title: Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
abstract: OBJECTIVE
  This multicenter, retrospective survey evaluated the efficacy and safety of bortezomib retreatment in patients with relapsed multiple myeloma who had responded to initial bortezomib treatment.
  
  
  METHODS
  Clinical records of 94 patients receiving bortezomib retreatment in Germany and Switzerland were reviewed.
  
  
  RESULTS
  Sixty patients were included according to prespecified criteria. Patients had received a mean 3.7 ± 2.3 therapies prior to initial bortezomib. Overall response rate to bortezomib retreatment was 63.3%; 8 (13.3%), 3 (5.0%) and 27 (45.0%) patients achieved complete response (CR), near-CR and partial response, respectively. Response to retreatment was associated with response to initial treatment (75.0% of patients with CR to initial treatment responded to retreatment) and treatment-free interval (TFI) after initial treatment (76.9 vs. 38.1% overall response rate for patients with TFI >6 vs. ≤ 6 months). After retreatment, median time to progression was 9.3 months. Median TFI was 5.7 months; 31.7, 25.0 and 15.0% of patients experienced a TFI longer than 6, 9 and 12 months, respectively. Reported adverse drug reactions were consistent with the known safety profile of bortezomib and most resolved completely.
  
  
  CONCLUSIONS
  These results demonstrate that relapsed multiple myeloma patients who respond to initial bortezomib treatment have a sustained susceptibility to bortezomib and do not experience uncommon toxicity to retreatment.
authors.affiliation: Diakonie-Krankenhaus, Schwäbisch Hall, Germany. Irena.Hrusovsky@diaksha.de
authors.forename: I
authors.initials: I
authors.lastname: Hrusovsky
authors.forename: B
authors.initials: B
authors.lastname: Emmerich
authors.forename: A
authors.initials: A
authors.lastname: von Rohr
authors.forename: J
authors.initials: J
authors.lastname: Voegeli
authors.forename: C
authors.initials: C
authors.lastname: Taverna
authors.forename: R A
authors.initials: RA
authors.lastname: Olie
authors.forename: H
authors.initials: H
authors.lastname: Pliskat
authors.forename: C
authors.initials: C
authors.lastname: Frohn
authors.forename: G
authors.initials: G
authors.lastname: Hess
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D018450:Disease Progression; D005260:Female; D005858:Germany; D006801:Humans; D007390:International Agencies; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D012074:Remission Induction; D019233:Retreatment; D012189:Retrospective Studies; D015996:Survival Rate; D013557:Switzerland; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib